Figure 2
From: P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development
P53-null MSCs show abnormal osteogenesis compared with the wild-type MSCs. In non-aberrant conditions, the expression of Osterix and Runx2 is upregulated during osteogenic differentiation of osteogenic committed cells to promote their differentiation and maturation towards osteoblasts and osteocytes, and to ensure a balanced bone remodeling (1). P53-null MSCs express before the commitment towards upregulated levels of both Osterix and Runx2. This compromises their differentiation towards mature osteoblasts and osteocytes, culminating in impaired bone remodeling and in the osteosclerotic phenotype observed in p53-deficient mice (2)
